Synthetic molecules as P2X7 receptor antagonists: A medicinal chemistry update focusing the therapy of inflammatory diseases.


Journal

European journal of pharmacology
ISSN: 1879-0712
Titre abrégé: Eur J Pharmacol
Pays: Netherlands
ID NLM: 1254354

Informations de publication

Date de publication:
15 Oct 2023
Historique:
received: 04 04 2023
revised: 12 07 2023
accepted: 17 08 2023
medline: 22 9 2023
pubmed: 25 8 2023
entrez: 24 8 2023
Statut: ppublish

Résumé

Stimulation of the P2X7 receptor by extracellular adenosine 5'-triphosphate induces a series of responses in the organism, exceptionally protein cascades related to the proinflammatory process. This has made P2X7 a target for research on inflammatory diseases such as rheumatoid arthritis. Thus, the incessant search for new prototypes that aim to antagonize the action of P2X7 has been remarkable in recent decades, a factor that has already led to numerous clinical studies in humans. In this review, we present the key molecules developed over the years with potential inhibition of P2X7 and inflammation. In addition, an update with newly developed chemical classes with promising activity and results in clinical studies for human pathologies focusing on P2X7 inhibition.

Identifiants

pubmed: 37619787
pii: S0014-2999(23)00511-3
doi: 10.1016/j.ejphar.2023.175999
pii:
doi:

Substances chimiques

Purinergic P2X Receptor Antagonists 0
Adenosine Triphosphate 8L70Q75FXE

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

175999

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

João Carlos Martins Mafra (JCM)

Laboratório de Síntese de Fármacos (LASFAR) - Farmanguinhos - Fiocruz Brazil; Instituto Federal do Rio de Janeiro - IFRJ, Rio de Janeiro, Brazil. Electronic address: joao.mafra@fiocruz.br.

Nubia Boechat (N)

Laboratório de Síntese de Fármacos (LASFAR) - Farmanguinhos - Fiocruz Brazil. Electronic address: nubia.boechat@fiocruz.br.

Guilherme Pegas Teixeira (GP)

Laboratório de Avaliação e Promoção da Saúde Ambiental, Instituto Oswaldo Cruz (IOC), Rio de Janeiro Fiocruz Brazil. Electronic address: gpegas67@gmail.com.

Robson Xavier Faria (RX)

Laboratório de Avaliação e Promoção da Saúde Ambiental, Instituto Oswaldo Cruz (IOC), Rio de Janeiro Fiocruz Brazil. Electronic address: robson.xavier@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH